Research suggests gut immune responses may activate Th17 cells in multiple sclerosis — Evidence Review

Scientists have identified a mechanism by which immune interactions in the gut may trigger multiple sclerosis (MS), showing that intestinal epithelial cells can activate pro-inflammatory Th17 cells that migrate to the central nervous system. Most related studies broadly support this gut-brain immune axis, reinforcing the idea that the gut microbiome and intestinal immunity play critical roles in MS pathogenesis, as described in this report from Keio University (opens in new tab).

• Several studies demonstrate that gut microbiome alterations in MS patients are linked to changes in immune cell populations, including Th17 cells, which are implicated in neuroinflammation and MS disease activity 1 4 9.
• Experimental models and human studies indicate that gut-derived immune cells, particularly Th17 cells, can migrate to the CNS and contribute to neuroinflammatory diseases, supporting the mechanistic pathway described in the new study 8 9 12.
• Some research suggests specific gut bacteria modulate these immune responses, and manipulating the gut environment may influence MS severity or progression, highlighting potential therapeutic avenues consistent with the new study’s implications 2 3 5.

Study Overview and Key Findings

While multiple sclerosis has traditionally been characterized as a disease of the brain and spinal cord, recent research has shifted focus toward the gut as a possible origin of immune dysregulation. The new study led by Dr. Shohei Suzuki and Dr. Tomohisa Sujino at Keio University investigates how immune responses in the intestinal lining may initiate and drive neuroinflammation linked to MS. By examining both mouse models and human biopsies, the researchers provide new evidence that the gut, particularly the activity of intestinal epithelial cells (IECs), plays a pivotal role in shaping immune responses that can lead to central nervous system autoimmunity.

Property	Value
Study Year	2026
Organization	Keio University
Journal Name	Science Immunology
Authors	Shohei Suzuki, Kentaro Miyamoto, Anna Tojo, Yusuke Yoshimatsu, Toshiaki Teratani, Hitoshi Uchida, Yasuhiro Nemoto, Ryuichi Okamoto, Andreas Michael Sihombing, Toshiro Sato, Jin Nakahara, Takanori Kanai, Tomohisa Sujino
Population	Patients with multiple sclerosis, EAE mouse model
Methods	Animal Study
Outcome	Gut immune responses and Th17 cell activation
Results	MHC II in IECs expands pathogenic Th17 cells migrating to CNS.

Literature Review: Related Studies

A review of the Consensus database, which contains over 200 million research papers, was conducted to identify studies relevant to the gut-brain-immune axis in multiple sclerosis and the specific immune mechanisms involved. The following search queries were used:

1. gut microbiome multiple sclerosis mechanisms
2. MHC II IECs Th17 cells CNS
3. pathogenic Th17 cells gut brain connection

Summary Table of Key Topics and Findings

Topic	Key Findings
How do gut microbiome changes influence MS development and progression?	- MS patients exhibit distinct gut microbiome alterations, including increased Akkermansia and Methanobrevibacter and decreased Butyricimonas and Faecalibacterium, correlating with immune dysregulation 1 4 5. - Fecal microbiota from MS patients can induce or exacerbate MS-like disease in mouse models, suggesting a causal role for microbiome composition in MS pathogenesis 2 3.
What is the role of Th17 cells in linking gut immunity and CNS autoimmunity in MS?	- High frequency of intestinal Th17 cells is associated with MS disease activity and specific microbiota profiles 9. - Homeostatic and stem-like intestinal Th17 cells can become pathogenic and contribute to CNS inflammation, with gut immune activation serving as a reservoir for encephalitogenic T cells 8.
Can specific gut-derived immune cell interactions be targeted to treat MS?	- Disrupting gut homing of Th17 cells or modulating IEC antigen presentation can reduce neuroinflammation in animal models, indicating that targeting gut immune mechanisms may confer therapeutic benefit [12, new study]. - Certain gut bacteria can modulate T cell responses; increasing beneficial species or suppressing pathogenic ones may alter disease outcomes 2 5.
How do gut microbiome alterations and immune responses differ by MS subtype or therapy?	- Microbiome composition varies with disease course (relapsing-remitting vs. progressive MS) and with disease-modifying treatments, affecting immune cell populations and metabolic pathways 4 5. - Some bacterial alterations, such as increased Akkermansia, may have differing roles depending on MS stage, potentially being beneficial in some contexts 5.

---

How do gut microbiome changes influence MS development and progression?

Multiple studies have established that MS patients display distinct alterations in their gut microbiome compared to healthy controls. These changes are not only compositional but also relate to immune function and may contribute to the onset and progression of MS. The new study builds on this foundation by elucidating a specific cellular mechanism through which gut immune responses may drive disease.

• MS patients show increased Akkermansia and Methanobrevibacter and decreased Butyricimonas and Faecalibacterium, correlating with immune dysregulation and MS risk 1 4 5.
• Transplanting fecal microbiota from MS patients into mice can induce or worsen MS-like disease, supporting a causal role of microbiome shifts in autoimmunity 2 3.
• Microbiome composition is influenced by disease-modifying treatments, which in turn alter immune pathways and metabolites 4.
• The new study provides a mechanistic link: it demonstrates that altered gut immune responses, driven by antigen presentation in IECs, can activate pathogenic Th17 cells that migrate to the CNS.

What is the role of Th17 cells in linking gut immunity and CNS autoimmunity in MS?

Th17 cells, a subset of pro-inflammatory T helper cells, have emerged as key players in MS pathogenesis. Several studies have shown that the gut environment is critical in driving the expansion and activation of these cells, which can then migrate to the CNS and contribute to neuroinflammation. The new study further clarifies this pathway by showing that IEC-driven antigen presentation is central to Th17 cell pathogenicity.

• Increased intestinal Th17 cell frequency is associated with higher MS disease activity and specific microbiota alterations 9.
• Homeostatic, stem-like Th17 cells in the gut can serve as a reservoir for pathogenic effector T cells that drive CNS autoimmunity 8.
• Th17 cells can promote neuroinflammation and activation of CNS-resident immune cells, contributing to neuronal damage 10 11.
• The new study demonstrates that IECs can directly activate and polarize Th17 cells, which then relocate to the CNS, providing a concrete mechanistic link between gut immunity and brain autoimmunity.

Can specific gut-derived immune cell interactions be targeted to treat MS?

The possibility of targeting gut immune mechanisms as a therapeutic strategy for MS is supported by both experimental and clinical findings. The new study suggests that modulating antigen presentation by IECs or altering the gut microbiota could be promising approaches.

• Disrupting gut homing of Th17 cells by blocking integrin pathways reduces neuroinflammation in mouse models 12.
• Manipulating the composition of the gut microbiota, either by promoting beneficial species or suppressing pathogenic ones, can influence T cell responses and ameliorate disease severity 2 5.
• The new study proposes that targeting IEC antigen presentation or the gut microbiome could be viable therapeutic strategies.
• These findings collectively point toward the gut as a modifiable site for intervention in MS and other neuroinflammatory diseases.

How do gut microbiome alterations and immune responses differ by MS subtype or therapy?

The microbiome and immune cell interactions are not uniform across all MS patients; they vary depending on disease subtype, disease activity, and treatment status. Understanding these differences is important for developing personalized interventions.

• The gut microbiome profile differs between relapsing-remitting and progressive MS, as well as with different disease-modifying therapies 4 5.
• Some alterations, such as increased Akkermansia, may be beneficial in progressive MS, contrary to earlier assumptions 5.
• Disease status, body mass index, and demographic variables also influence microbiome diversity and immune profiles 4.
• These complexities suggest that future therapeutic approaches may need to be tailored to individual patient profiles, considering both gut microbiome and immune system status.

Future Research Questions

While the new study advances understanding of the gut-brain immune axis in MS, several important questions remain. Future research should aim to clarify the clinical relevance of these findings in humans, explore therapeutic interventions, and investigate how gut-brain-immune interactions vary across MS subtypes and patient populations.

Research Question	Relevance
Does modulating intestinal epithelial cell antigen presentation reduce MS activity in humans?	Determining if interventions that target IEC antigen presentation can decrease MS activity in patients would validate the translational potential of the new mechanism described [12, new study].
Which specific gut microbes promote or suppress pathogenic Th17 cell activation in MS?	Identifying key microbial species that influence Th17 cell differentiation could inform targeted probiotic or dietary therapies for MS 2 3 4 5 9.
How do gut immune mechanisms differ between relapsing-remitting and progressive MS?	Understanding mechanistic differences between MS subtypes may help tailor interventions and explain differential responses to microbiome-targeted therapies 4 5.
What is the long-term effect of altering the gut microbiome on MS progression and severity?	Longitudinal studies are needed to assess whether sustained changes to the gut microbiome can modify disease course and outcomes in MS patients 2 3 4 5.
Can combining gut-targeted immunotherapies with existing MS treatments improve clinical outcomes?	Evaluating combination therapies could determine if targeting both systemic and gut-derived immune mechanisms is more effective than current approaches alone 4 12.